Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelistotug - GSK

Next Previous
Drug Profile

Nelistotug - GSK

Alternative Names: GSK-6097608; GSK’608; GSK’608 CD96

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer 23andMe; GSK
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD96 antigen inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 29 Oct 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Japan, Canada, South Korea, USA (IV) (GSK pipeline, October 2025)
  • 29 Oct 2025 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in USA, Japan, South Korea, Canada (IV) (GSK pipeline, October 2025)
  • 29 Oct 2025 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Canada, France, Germany, Italy, Russia, Netherlands, Romania, Spain, South Korea, Poland, Sweden (Parenteral) (GSK pipeline, October 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top